72 completed, 13 terminated, 3 withdrawn, 2 active not recruiting. 49 Phase 1, 48 Phase 2, 9 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Recurrent Adult Hodgkin Lymphoma: new trials by email Literature Review of Recurrent Adult Hodgkin Lymphoma trials Research Report on Recurrent Adult Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma carmustine, cytarabine, melphalan - Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma | Not applicable | Withdrawn | Fred Hutchinson Cancer Center | 2015-02-01 | 2015-05-07 | |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer everolimus, bendamustine hydrochloride - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | University of California, Davis | 20 | 2014-10-01 | 2019-01-04 |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 3 | 2013-09-01 | 2015-11-09 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma basiliximab, carmustine, etoposide - Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 25 | 2013-02-13 | 2026-10-15 |
| Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Brentuximab Vedotin, Gemcitabine Hydrochloride - Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2013-01-31 | 2021-10-28 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant management of therapy complications, musculoskeletal complications management/prevention - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2012-05-01 | 2012-07-09 | |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2012-04-16 | 2018-04-11 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma gemcitabine hydrochloride, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Beth Christian | 26 | 2012-02-09 | 2021-11-19 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Phase 1 | Completed | Robert Lowsky | 16 | 2012-01-01 | 2023-11-22 |
| A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma panobinostat, lenalidomide - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 24 | 2011-10-13 | 2017-11-14 |
Showing 20 of 91. Sign in to see all of them.
Hodgkin Disease (91) · Leukemia, Lymphocytic, Chronic, B-Cell (74) · Lymphoma, Follicular (74) · Lymphoma, Mantle-Cell (72) · Lymphoma, Non-Hodgkin (72) · Lymphoma, B-Cell, Marginal Zone (71) · Lymphoma, Large B-Cell, Diffuse (70) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (68) · Burkitt Lymphoma (66) · Lymphoma, Large-Cell, Immunoblastic (62) · Lymphoma, T-Cell, Cutaneous (62) · Mycosis Fungoides (61) · Sezary Syndrome (61) · Waldenstrom Macroglobulinemia (59) · Lymphoma, Large-Cell, Anaplastic (54)
Hemic and Lymphatic Diseases (91) · Immune System Diseases (91) · Immunoproliferative Disorders (91) · Lymphatic Diseases (91) · Lymphoma (91) · Lymphoproliferative Disorders (91) · Neoplasms by Histologic Type (91) · Neoplasms (90) · Hematologic Diseases (78) · Disease Attributes (77) · Leukemia (77) · Leukemia, Lymphoid (77) · Pathologic Processes (77) · Pathological Conditions, Signs and Symptoms (77) · Lymphoma, B-Cell (76)
Peripheral Blood Stem Cell Transplantation (21) · Whole-Body Irradiation (18) · fludarabine phosphate (18) · Mycophenolic Acid (15) · Cyclosporine (11) · Etoposide (10) · Cyclophosphamide (9) · Tacrolimus (9) · Melphalan (8) · Bendamustine Hydrochloride (7) · Rituximab (7) · Carmustine (6) · Gemcitabine (6) · Vorinostat (6) · Busulfan (5)
National Cancer Institute (NCI) (37) · Fred Hutchinson Cancer Center (21) · City of Hope Medical Center (5) · Roswell Park Cancer Institute (4) · Case Comprehensive Cancer Center (3) · University of Washington (3) · Mayo Clinic (2) · Wake Forest University Health Sciences (2) · AIDS Malignancy Consortium (1) · Amir Mortazavi (1) · Beth Christian (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (1) · Martin, Paul (1) · Morphotek (1)
United States (89) · Italy (8) · Germany (6) · Canada (2) · Denmark (1)
Brenda Sandmaier (6) · Ajay Gopal (5) · David Maloney (5) · Paul Martin (3) · Anas Younes (2) · George Chen (2) · Mehrdad Abedi (2) · Patricia LoRusso (2) · Philip McCarthy (2) · Ramesh Ramanathan (2) · Ryotaro Nakamura (2) · Adam Petrich, MD (1) · Alison Moskowitz (1) · Amir Mortazavi, MD (1) · Ann Woolfrey (1)
PMID 32499241, PMID 18974373, PMID 19900571, PMID 21725056, PMID 22259028, PMID 24241210, PMID 24474568, PMID 25085357, PMID 25833390, PMID 26213141, PMID 26764356, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28314788, PMID 28622959, PMID 28817727, PMID 29292843, PMID 29572391, PMID 30122620, PMID 30562587, PMID 30596402, PMID 31481800, PMID 31617432, PMID 32628342, PMID 33420905, PMID 33492438, PMID 34320785, PMID 34638132, PMID 36282798
P30CA015704 (16), P01CA018029 (6), P30CA015083 (4), U01CA062487 (4), U01CA062491 (4), U01CA099168 (4), P01CA078902 (3), P30CA016672 (3), U01CA062505 (3), U01CA069912 (3), N01CM17003 (2), P30CA008748 (2), P30CA016058 (2), U01CA062502 (2), U01CA069856 (2)